Richard A. Brigandi

A Novel Hypoxia-Inducible Factor−Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial

Richard A. Brigandi, Brendan M. Johnson, Coreen Oei et al. · American Journal of Kidney Diseases · 2016 · 159 citations · Full text

Medicine, Hematology, Pharmacology +17

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Andrew Spencer, Sung‐Soo Yoon, Simon J. Harrison et al. · Blood · 2014 · 140 citations

Medicine, Pharmacokinetics, Pharmacology +11

Strongyloides stercoralis:Eosinophil-Dependent Immune-Mediated Killing of Third Stage Larvae in BALB/cByJ Mice

Harris L. Rotman, Wiboonchai Yutanawiboonchai, Richard A. Brigandi et al. · Experimental Parasitology · 1996 · 103 citations · Full text

Veterinary Medicine, Immunology, Pathology +17

Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection

John G. McHutchison, Zachary Goodman, Keyur Patel et al. · Gastroenterology · 2009 · 93 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Candidate Selection and Preclinical Evaluation of <i>N</i> - <i>tert</i> -Butyl Isoquine (GSK369796), An Affordable and Effective 4-Aminoquinoline Antimalarial for the 21st Century

Paul M. O’Neill, B. Kevin Park, Alison E. Shone et al. · Journal of Medicinal Chemistry · 2009 · 84 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16